Translating cancer genomes and transcriptomes for pre-

Ca-A Cancer Journal for Clinicians 66, 75-88 DOI: 10.3322/caac.21329

Citation Report

#	Article	IF	CITATIONS
1	Big Data for Cancer Research. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S38279.	0.6	5
2	CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget, 2016, 7, 52541-52552.	0.8	68
3	Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open, 2016, 1, e000094.	2.0	126
4	K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. Medical Oncology, 2016, 33, 61.	1.2	21
5	Differential gene expression in brain and peripheral tissues in depression across the life span: A review of replicated findings. Neuroscience and Biobehavioral Reviews, 2016, 71, 281-293.	2.9	26
6	Liquid Biopsies. Medizinische Genetik, 2016, 28, 245-250.	0.1	0
7	Intratumor heterogeneity: predicting and preventing therapeutic resistance. Biomarkers in Medicine, 2016, 10, 681-684.	0.6	2
8	The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker Research, 2016, 4, 8.	2.8	6
9	Precision medicine in cardiology. Nature Reviews Cardiology, 2016, 13, 591-602.	6.1	183
10	New challenges to psychoâ€oncology research: Precision medicine oncology and targeted therapies. Psycho-Oncology, 2017, 26, 144-146.	1.0	10
11	Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Scientific Reports, 2017, 7, 42980.	1.6	27
12	Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development. Expert Opinion on Drug Discovery, 2017, 12, 733-745.	2.5	3
13	Drug induces depression-like phenotypes and alters gene expression profiles in Drosophila. Brain Research Bulletin, 2017, 132, 222-231.	1.4	15
14	Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?. Npj Precision Oncology, 2017, 1, 21.	2.3	21
15	Androgen receptor and miR-206 regulation in prostate cancer. Transcription, 2017, 8, 313-327.	1.7	15
16	Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models. Scientific Reports, 2017, 7, 44831.	1.6	10
17	Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discovery Today, 2017, 22, 1148-1164.	3.2	30
18	Transcriptome modeling and phenotypic assays for cancer precision medicine. Archives of Pharmacal Research, 2017, 40, 906-914.	2.7	7

ATION RED

#	Article	IF	CITATIONS
19	The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Scientific Reports, 2017, 7, 17193.	1.6	50
20	Personalized medicine—a modern approach for the diagnosis and management of hypertension. Clinical Science, 2017, 131, 2671-2685.	1.8	59
21	Translating cancer epigenomics into the clinic: focus on lung cancer. Translational Research, 2017, 189, 76-92.	2.2	40
22	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey–Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 123-144.	1.2	6
23	DNA Demethylation Agents in Clinical Medicine. , 2017, , 595-603.		1
24	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget, 2017, 8, 89848-89866.	0.8	45
25	Communicating About Precision Oncology. JCO Precision Oncology, 2017, 1, 1-9.	1.5	7
26	Harnessing Solute Carrier Transporters for Precision Oncology. Molecules, 2017, 22, 539.	1.7	33
27	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. International Journal of Molecular Sciences, 2017, 18, 180.	1.8	16
28	Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. Journal of Cancer, 2017, 8, 513-522.	1.2	36
29	Nanomaterials for Cancer Precision Medicine. Advanced Materials, 2018, 30, e1705660.	11.1	136
30	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clinical Cancer Research, 2018, 24, 2719-2731.	3.2	54
31	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends in Cancer, 2018, 4, 101-109.	3.8	56
32	A novel prognostic sixâ€CpG signature in glioblastomas. CNS Neuroscience and Therapeutics, 2018, 24, 167-177.	1.9	30
33	Diagnosis and management of metastatic neoplasms with unknown primary. Seminars in Diagnostic Pathology, 2018, 35, 199-206.	1.0	46
34	From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Medicine, 2018, 10, 18.	3.6	36
35	Pancreatic cancer subtypes: a roadmap for precision medicine. Annals of Medicine, 2018, 50, 277-287.	1.5	69
36	Sprouty2 lossâ€induced IL 6 drives castrationâ€resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 2018, 10, .	3.3	19

#	Article	IF	CITATIONS
37	Realizing the Promise of Cognitive Computing in Cancer Care: Ushering in a New Era. JCO Clinical Cancer Informatics, 2018, 2, 1-6.	1.0	7
38	Identification of candidate target genes for endometrial cancer, such as ANO1, using weighted gene co‑expression network analysis. Experimental and Therapeutic Medicine, 2018, 17, 298-306.	0.8	9
40	Oncogenic Amplification of Zygotic Dux Factors in Regenerating p53-Deficient Muscle Stem Cells Defines a Molecular Cancer Subtype. Cell Stem Cell, 2018, 23, 794-805.e4.	5.2	21
41	Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy. Inorganics, 2018, 6, 126.	1.2	64
42	Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer, 2018, 18, 911.	1.1	25
43	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. BMC Medical Informatics and Decision Making, 2018, 18, 89.	1.5	18
44	The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care. Frontiers in Oncology, 2018, 8, 340.	1.3	20
45	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology, 2018, 18, 647-654.	0.5	35
46	Applications of RNA Indexes for Precision Oncology in Breast Cancer. Genomics, Proteomics and Bioinformatics, 2018, 16, 108-119.	3.0	16
47	Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer, 2018, 124, 3052-3065.	2.0	14
48	Personalization of prostate cancer therapy through phosphoproteomics. Nature Reviews Urology, 2018, 15, 483-497.	1.9	25
49	Clinical Utility of Nextâ€generation Sequencing in the Management of Myeloproliferative Neoplasms: A Singleâ€Center Experience. HemaSphere, 2018, 2, e44.	1.2	19
50	Role of COL6A3 in colorectal cancer. Oncology Reports, 2018, 39, 2527-2536.	1.2	37
51	Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. Molecular Genetics and Genomics, 2018, 293, 1217-1229.	1.0	0
52	Cancer immunotherapy for metastasis: past, present and future. Briefings in Functional Genomics, 2019, 18, 140-146.	1.3	10
53	New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1173.	1.0	27
54	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica, 2019, 138, 1053-1074.	3.9	106
55	Transcriptomic characterisation of the optimised rat model of Walker 256 breast cancer cellâ€induced bone pain. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 1201-1215.	0.9	2

#	Article	IF	CITATIONS
56	Single-cell RNA-seq of esophageal squamous cell carcinoma cell line with fractionated irradiation reveals radioresistant gene expression patterns. BMC Genomics, 2019, 20, 611.	1.2	23
57	Current omics-based biomarkers for cholangiocarcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 997-1005.	1.5	7
58	Oncoproteomics: Current status and future opportunities. Clinica Chimica Acta, 2019, 495, 611-624.	0.5	20
59	Palliative Care in Chronic Illness and Multimorbidity. , 2019, , 1173-1187.		0
60	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Clinical Epigenetics, 2019, 11, 76.	1.8	14
61	Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. Clinical Proteomics, 2019, 16, 15.	1.1	15
62	Genome-scale network model of metabolism and histone acetylation reveals metabolic dependencies of histone deacetylase inhibitors. Genome Biology, 2019, 20, 49.	3.8	33
63	Exploiting rare driver mutations for precision cancer medicine. Current Opinion in Genetics and Development, 2019, 54, 1-6.	1.5	13
64	Recent developments in genetic/genomic medicine. Clinical Science, 2019, 133, 697-708.	1.8	80
65	Experimental Design in Quantitative Proteomics. Methods in Molecular Biology, 2019, 1977, 181-197.	0.4	2
66	<i>TP53</i> gene rs1042522 allele G decreases neuroblastoma risk: a two-centre case-control study. Journal of Cancer, 2019, 10, 467-471.	1.2	9
67	PROMO: an interactive tool for analyzing clinically-labeled multi-omic cancer datasets. BMC Bioinformatics, 2019, 20, 732.	1.2	22
68	Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma. Cancer Biomarkers, 2019, 24, 71-83.	0.8	24
69	Gene Editing in Clinical Practice: Where are We?. Indian Journal of Clinical Biochemistry, 2019, 34, 19-25.	0.9	10
70	A Computational Protocol for Detecting Somatic Mutations by Integrating DNA and RNA Sequencing. Methods in Molecular Biology, 2019, 1878, 109-124.	0.4	0
71	Transcriptome Sequencing (RNA-Seq). , 2019, , 33-49.		1
72	Tumorâ€Specific Transcripts Are Frequently Expressed in Hepatocellular Carcinoma With Clinical Implication and Potential Function. Hepatology, 2020, 71, 259-274.	3.6	16
73	Deep learning of pharmacogenomics resources: moving towards precision oncology. Briefings in Bioinformatics, 2020, 21, 2066-2083.	3.2	43

#	Article	IF	CITATIONS
74	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nature Communications, 2020, 11, 5679.	5.8	41
75	PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Science Translational Medicine, 2020, 12, .	5.8	23
76	Machine Learning Models to Predict Primary Sites of Metastatic Cervical Carcinoma From Unknown Primary. Frontiers in Genetics, 2020, 11, 614823.	1.1	1
77	A gene-based survival score for lung adenocarcinoma by multiple transcriptional datasets analysis. BMC Cancer, 2020, 20, 1046.	1.1	4
78	Gene Expression: the Key to Understanding HIV-1 Infection?. Microbiology and Molecular Biology Reviews, 2020, 84, .	2.9	9
79	VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 83.	6.9	118
80	Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093855.	1.0	8
81	Clinical implications of intratumor heterogeneity: challenges and opportunities. Journal of Molecular Medicine, 2020, 98, 161-177.	1.7	241
82	Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precision Oncology, 2020, 4, 258-271.	1.5	16
83	Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis. Annals of Translational Medicine, 2020, 8, 284-284.	0.7	3
84	Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology. Frontiers in Oncology, 2020, 10, 447.	1.3	72
85	Blueprint for cancer research: Critical gaps and opportunities. Ca-A Cancer Journal for Clinicians, 2021, 71, 107-139.	157.7	47
86	Robustness of differential gene expression analysis of RNA-seq. Computational and Structural Biotechnology Journal, 2021, 19, 3470-3481.	1.9	39
87	Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. International Journal of Molecular Sciences, 2021, 22, 1422.	1.8	64
88	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research, 2021, 27, 2807-2815.	3.2	12
89	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. European Urology Oncology, 2022, 5, 430-439.	2.6	8
90	Characterizing the Expression Patterns of Parkinson's Disease Associated Genes. Frontiers in Neuroscience, 2021, 15, 629156.	1.4	6
91	A multiparametric extraction method for Vn96-isolated plasma extracellular vesicles and cell-free DNA that enables multi-omic profiling. Scientific Reports, 2021, 11, 8085.	1.6	8

#	Article	IF	CITATIONS
92	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics, 2021, 11, 1195.	1.3	9
93	Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study. Journal of Gastrointestinal Surgery, 2021, 25, 3149-3159.	0.9	12
94	Diagnostic Pathology in the Era of Precision Medicine. The Journal of Bahria University Medical and Dental College, 2021, 11, 100-101.	0.0	0
95	Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. Oncolmmunology, 2021, 10, 1902071.	2.1	8
96	Epigenetics of Circulating Tumor Cells in Breast Cancer. Advances in Experimental Medicine and Biology, 2020, 1220, 117-134.	0.8	14
98	Gene expression-based clinical predictions in lung adenocarcinoma. Aging, 2020, 12, 15492-15503.	1.4	4
99	Population and single‑cell transcriptome analyses reveal diverse transcriptional changes associated with radioresistance in esophageal squamous cell carcinoma. International Journal of Oncology, 2019, 55, 1237-1248.	1.4	11
100	Effect of method of deduplication on estimation of differential gene expression using RNA-seq. PeerJ, 2017, 5, e3091.	0.9	22
101	Palliative Care in Chronic Illness and Multimorbidity. , 2018, , 1-15.		1
102	Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors. , 2018, , 1-30.		0
105	Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors. , 2019, , 2709-2737.		0
106	Experimental Approaches for Genome Sequencing. , 2019, , 159-165.		1
107	5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer. Frontiers in Molecular Biosciences, 2021, 8, 775304.	1.6	19
108	Update of gene expression/methylation and MiRNA profiling in colorectal cancer; application in diagnosis, prognosis, and targeted therapy. PLoS ONE, 2022, 17, e0265527.	1.1	1
110	Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, 2022, 21, 64.	7.9	45
111	Primary liver cancer genome sequencing: translational implications and challenges. Expert Review of Castroenterology and Hepatology, 2017, 11, 875-883.	1.4	3
112	ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth. Medical Oncology, 2022, 39, 64.	1.2	3
113	Comparative characterization of 3D chromatin organization in triple-negative breast cancers. Experimental and Molecular Medicine, 2022, 54, 585-600.	3.2	12

# ARTICLE IF CITATION 114 Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer. Saudi Journal of Biological Sciences, 2022, 29, 103318. 1.8 3 115 Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating 0.6 3 117 Allowed Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP 0.6 1 118 Deeper insights into long term sumival heterogeneity of panceatic ductal adenocarcinoma (PDAC) 1.6 2 119 Next-generation sequencing identifies potential novel therapeutic targets in Chinese HCSOC patients. 1.0 4 120 OCICNAccylation: an Important post-translational modification and a potential therapeutic target for accer therapy. Molecular Medicine, 2022, 28. 1.0 4 121 Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022, .1. 0 1.0 4 122 Challenges and hopes in CRISPR CAS technology in future., 0, 5-12. 0 2 4 123 Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology. 0.6 2 122 Stromal				
114Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer. Saudi Journal of Biological Sciences, 2022, 29, 103318.1.83115Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis. Disease Markers, 2022, 2022, 1-21.0.61117A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Ciloblastomas. Journal of Oncology, 2022, 2022, 1-15.0.61118Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Scientific Pathology Research and Practice, 2022, 238, 154074.1.04119Next-generation sequencing identifies potential novel therapeutic targets in Chinese HCSOC patients. Pathology Research and Practice, 2022, 28, 154074.1.01120OCIeNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Molecular Medicine, 2022, 28,0121Advances in liquid biops in neuroblastoma. Fundamental Research, 2022,1.61122Challenges and hopes in CRISPR CAS technology in future. , 0, , 5-12.0123Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, transcriptome. Med, 2023, 4, 15-30.2.24124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 24	#	Article	IF	CITATIONS
119Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis. Disease Markers, 2022, 2022, 1-21.0.61117Allovel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP patients using integrative individual- and group-level transcriptome network analyses. Scientific Reports, 2022, 12.0.61118Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Scientific Reports, 2022, 12.1.62119Next-generation sequencing identifies potential novel therapeutic targets in Chinese HCSOC patients. Pathology Research and Practice, 2022, 238, 154074.1.04120O-CIcNA-yslation: an important post-translational modification and a potential therapeutic target for cancer therapy. Molecular Medicine, 2022, 28,1.61121Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022,0.62122Challenges and hopes in CRISPR CAS technology in future. , 0, , 5-12.0123Stromal Interaction Molecular I (STIM1) is a Potential Prognostic Biomarker and Correlates with 2023, 42, 11-30.2.2124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 42, 15-30.e8.2.2125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.1.2126Clinically oriented prediction of Pro-coagulation Genes is a Predictor of Anglogenesis, Epithelial M	114	Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer. Saudi Journal of Biological Sciences, 2022, 29, 103318.	1.8	3
117A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP0.61118Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Scientific1.62119Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.1.04120O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Molecular Medicine, 2022, 28.1.61121Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022,1.61122Challenges and hopes in CRISPR CAS technology in future. , 0, 5-12.0123Stromal Interaction Molecule 1 (STIMI) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.2.2124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 27,3, 104810.2.2125OSppc: A web server for online survival analysis using proteome of pancancers. Journal of Proteomics, 2023, 27,3, 104810.1.2126Higher Intra-Tumoral Expression of Proccagulation Genes Is a Predictor of Anglogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Castric Cancer. Journal of the American Bestenchymal Transition and Worse Patient Survival in Castric Cancer. Journal of the American Mesenchymal Transition and Worse Patient Survival in Castric Cancer. Journal of the American0.2 <td>115</td> <td>Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis. Disease Markers, 2022, 2022, 1-21.</td> <td>0.6</td> <td>3</td>	115	Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis. Disease Markers, 2022, 2022, 1-21.	0.6	3
118Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Scientific Reports, 2022, 12, .1.62119Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. Pathology Research and Practice, 2022, 238, 154074.1.04120O-ClcNAcylation: an important post-translational modification and a potential therapeutic target for 	117	A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas. Journal of Oncology, 2022, 2022, 1-15.	0.6	1
119Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.1.04120O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Molecular Medicine, 2022, 28, .1.91.4121Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022, .1.61122Challenges and hopes in CRISPR CAS technology in future. , 0, .5-12.0123Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.2.24124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor 	118	Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. Scientific Reports, 2022, 12, .	1.6	2
120O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Molecular Medicine, 2022, 28, .1.914121Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022, , .1.61122Challenges and hopes in CRISPR CAS technology in future. , 0, , 5-12.0123Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.0.62124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.2.24125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.1.23126Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Gastric Cancer. Journal of the American College of Surgeons, 2023, 236, S106-S107.0.20	119	Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. Pathology Research and Practice, 2022, 238, 154074.	1.0	4
121Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022, , .1.61122Challenges and hopes in CRISPR CAS technology in future., 0, , 5-12.0123Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.0.62124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.2.24125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of 	120	O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy. Molecular Medicine, 2022, 28, .	1.9	14
122Challenges and hopes in CRISPR CAS technology in future. , 0, , 5-12.0123Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.0.62124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.2.24125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.1.23126Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Castric Cancer. Journal of the American College of Surgeons, 2023, 236, S106-S107.0.20	121	Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022, , .	1.6	1
Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.0.62124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.2.24125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.1.23126Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Gastric Cancer. Journal of the American0.20	122	Challenges and hopes in CRISPR CAS technology in future. , 0, , 5-12.		0
124Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.2.24125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.1.23126Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Gastric Cancer. Journal of the American0.20	123	Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors. Journal of Environmental Pathology, Toxicology and Oncology, 2023, 42, 11-30.	0.6	2
125OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.1.23126Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Gastric Cancer. Journal of the American0.20	124	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.	2.2	4
Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial 126 Mesenchymal Transition and Worse Patient Survival in Gastric Cancer. Journal of the American 0.2 0 College of Surgeons, 2023, 236, S106-S107.	125	OSppc: A web server for online survival analysis using proteome of pan-cancers. Journal of Proteomics, 2023, 273, 104810.	1.2	3
	126	Higher Intra-Tumoral Expression of Pro-coagulation Genes Is a Predictor of Angiogenesis, Epithelial Mesenchymal Transition and Worse Patient Survival in Gastric Cancer. Journal of the American College of Surgeons, 2023, 236, S106-S107.	0.2	0

130 Palliative Care in Chronic Illness and Multimorbidity. , 2023, , 1-16.

CITATION REPORT